GBT
HZNP

Grove Bank & Trust’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Grove Bank & Trust’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150
Closed -$17.4K – 743
2023
Q3 		$17.4K Hold
150
– – ﹤0.01% 470
2023
Q2 		$15.4K Hold
150
– – ﹤0.01% 468
2023
Q1 		$16.4K Hold
150
– – ﹤0.01% 475
2022
Q4 		$17K Buy
+150
New +$12.5K ﹤0.01% 470

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Grove Bank & Trust's HZNP Position: Q4 2023 in Review

Grove Bank & Trust sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 150 shares — an estimated $17.4K sold.

Grove Bank & Trust first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $17.4K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Grove Bank & Trust reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Grove Bank & Trust sold 150 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $17.4K.
  • Grove Bank & Trust first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Grove Bank & Trust's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $17.4K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.